Advances in Cancer Research: Current and Future Diagnostic and Therapeutic Strategies

Overview

Journal Biosensors (Basel)

Specialty Biotechnology

Date 2024 Feb 23

PMID 38392019

Authors

Xiaohui Liu

Hui Jiang

Xuemei Wang

Affiliations

Soon will be listed here.

Abstract

Cancers of unknown primary (CUP) exhibit significant cellular heterogeneity and malignancy, which poses significant challenges for diagnosis and treatment. Recent years have seen deeper insights into the imaging, pathology, and genetic characteristics of CUP, driven by interdisciplinary collaboration and the evolution of diagnostic and therapeutic strategies. However, due to their insidious onset, lack of evidence-based medicine, and limited clinical understanding, diagnosing and treating CUP remain a significant challenge. To inspire more creative and fantastic research, herein, we report and highlight recent advances in the diagnosis and therapeutic strategies of CUP. Specifically, we discuss advanced diagnostic technologies, including 12-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) or Ga-FAPI (fibroblast activation protein inhibitor) PET/CT, liquid biopsy, molecular diagnostics, self-assembling nanotechnology, and artificial intelligence (AI). In particular, the discussion will extend to the effective treatment techniques currently available, such as targeted therapies, immunotherapies, and bio-nanotechnology-based therapeutics. Finally, a novel perspective on the challenges and directions for future CUP diagnostic and therapeutic strategies is discussed.

Citing Articles

Enhancing Drug Solubility, Bioavailability, and Targeted Therapeutic Applications through Magnetic Nanoparticles.

Zhuo Y, Zhao Y, Zhang Y Molecules. 2024; 29(20).

PMID: 39459222 PMC: 11510236. DOI: 10.3390/molecules29204854.

Stimulus-Responsive Hydrogels for Targeted Cancer Therapy.

Solanki R, Bhatia D Gels. 2024; 10(7).

PMID: 39057463 PMC: 11275390. DOI: 10.3390/gels10070440.

References

Liu X, Li H, Zhao Y, Yu X, Xu D . Multivalent aptasensor array and silver aggregated amplification for multiplex detection in microfluidic devices. Talanta. 2018; 188:417-422. DOI: 10.1016/j.talanta.2018.05.048. View

Haratani K, Hayashi H, Takahama T, Nakamura Y, Tomida S, Yoshida T . Clinical and immune profiling for cancer of unknown primary site. J Immunother Cancer. 2019; 7(1):251. PMC: 6743146. DOI: 10.1186/s40425-019-0720-z. View

Lu M, Chen T, Williamson D, Zhao M, Shady M, Lipkova J . AI-based pathology predicts origins for cancers of unknown primary. Nature. 2021; 594(7861):106-110. DOI: 10.1038/s41586-021-03512-4. View

Zhang P, Zhou X, He M, Shang Y, Tetlow A, Godwin A . Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip. Nat Biomed Eng. 2019; 3(6):438-451. PMC: 6556143. DOI: 10.1038/s41551-019-0356-9. View

Huey R, Shah A, Reddi H, Dasari P, Topham J, Hwang H . Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study. J Natl Cancer Inst. 2023; 115(8):994-997. PMC: 10407690. DOI: 10.1093/jnci/djad095. View

Tanaka H, Suzuki M, Takemoto N, Fukusumi T, Eguchi H, Takai E . Performance of oral HPV DNA, oral HPV mRNA and circulating tumor HPV DNA in the detection of HPV-related oropharyngeal cancer and cancer of unknown primary. Int J Cancer. 2021; 150(1):174-186. PMC: 9290341. DOI: 10.1002/ijc.33798. View

Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y . Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Ann Oncol. 2021; 33(2):216-226. DOI: 10.1016/j.annonc.2021.11.009. View

Bentestuen M, Al-Obaydi N, Zacho H . FAPI-avid nonmalignant PET/CT findings: An expedited systematic review. Semin Nucl Med. 2023; 53(5):694-705. DOI: 10.1053/j.semnuclmed.2023.02.001. View

Moon I, Lopiccolo J, Baca S, Sholl L, Kehl K, Hassett M . Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary. Nat Med. 2023; 29(8):2057-2067. PMC: 11484892. DOI: 10.1038/s41591-023-02482-6. View

10.

Kato S, Krishnamurthy N, Banks K, De P, Williams K, Williams C . Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. Cancer Res. 2017; 77(16):4238-4246. PMC: 5729906. DOI: 10.1158/0008-5472.CAN-17-0628. View

11.

Girard A, Vila Reyes H, Shaish H, Grellier J, Dercle L, Salaun P . The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma. Front Oncol. 2020; 10:565086. PMC: 7574640. DOI: 10.3389/fonc.2020.565086. View

12.

Tang J, Zhang X, Cheng L, Liu Y, Chen Y, Jiang Z . Multiple stimuli-responsive nanosystem for potent, ROS-amplifying, chemo-sonodynamic antitumor therapy. Bioact Mater. 2022; 15:355-371. PMC: 8935089. DOI: 10.1016/j.bioactmat.2021.12.002. View

13.

Lone S, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S . Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022; 21(1):79. PMC: 8932066. DOI: 10.1186/s12943-022-01543-7. View

14.

Rassy E, Boussios S, Pavlidis N . Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary. Eur J Clin Invest. 2021; 51(9):e13583. DOI: 10.1111/eci.13583. View

15.

Laprovitera N, Salamon I, Gelsomino F, Porcellini E, Riefolo M, Garonzi M . Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches. Front Cell Dev Biol. 2021; 9:666156. PMC: 8222689. DOI: 10.3389/fcell.2021.666156. View

16.

Laprovitera N, Riefolo M, Porcellini E, Durante G, Garajova I, Vasuri F . MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary. Mol Oncol. 2021; 15(10):2732-2751. PMC: 8486570. DOI: 10.1002/1878-0261.13026. View

17.

Ross J, Wang K, Gay L, Otto G, White E, Iwanik K . Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. JAMA Oncol. 2015; 1(1):40-49. DOI: 10.1001/jamaoncol.2014.216. View

18.

Wu M, Ouyang Y, Wang Z, Zhang R, Huang P, Chen C . Isolation of exosomes from whole blood by integrating acoustics and microfluidics. Proc Natl Acad Sci U S A. 2017; 114(40):10584-10589. PMC: 5635903. DOI: 10.1073/pnas.1709210114. View

19.

Greco F, Oien K, Erlander M, Osborne R, Varadhachary G, Bridgewater J . Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol. 2011; 23(2):298-304. DOI: 10.1093/annonc/mdr306. View

20.

Rosenwald S, Gilad S, Benjamin S, Lebanony D, Dromi N, Faerman A . Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol. 2010; 23(6):814-23. DOI: 10.1038/modpathol.2010.57. View